Clinical Analysis of Icotinib on Beneficiary of 
Advanced Non-small Cell Lung Cancer with EGFR Common Mutation

Background and objective Targeted therapy has become an indispensable therapy method in advanced non-small cell lung cancer (NSCLC) treatment. Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can significantly prolong the survival of patients harboring EGFR gene mutation. Ico...

Descripción completa

Detalles Bibliográficos

Autores principales:	Xiaowen JIANG, Wenxian WANG, Yiping ZHANG
Formato:	Artigo
Lenguaje:	Chinês
Publicado:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2016-04-01
Colección:	Chinese Journal of Lung Cancer
Materias:	Lung neoplasms EGFR mutation Icotinib Beneficiary
Acceso en línea:	http://dx.doi.org/10.3779/j.issn.1009-3419.2016.04.04
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!